We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.
- Authors
Hussain, Maha H A; MacVicar, Gary R; Petrylak, Daniel P; Dunn, Rodney L; Vaishampayan, Ulka; Lara, Primo N, Jr; Chatta, Gurkamal S; Nanus, David M; Glode, L Michael; Trump, Donald L; Chen, Helen; Smith, David C; National Cancer Institute
- Abstract
We investigated the safety and efficacy (response rates, time to disease progression, survival) of trastuzumab, carboplatin, gemcitabine, and paclitaxel in advanced urothelial carcinoma patients and prospectively evaluated human epidermal growth factor receptor-2 (Her-2/neu) overexpression rates.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Vol 25, Issue 16, p2218
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2006.08.0994